Breaking News Instant updates and real-time market news.

SLDB

Solid Biosciences

$8.86

-0.3397 (-3.69%)

, SRPT

Sarepta

$112.12

-9.97 (-8.17%)

08:35
05/14/19
05/14
08:35
05/14/19
08:35

Solid Biosciences downgraded to Underperform at Credit Suisse

As previously reported, Credit Suisse analyst Martin Auster (SLDB) downgraded Solid Biosciences to Underperform from Neutral as he sees enrollment challenges and pressured timelines ahead. Earlier this year, Solid presented underwhelming initial microdystrophin data for the three patients at the low dose, necessitating dose escalation from 5E13 vg/kg to 2E14 vg/kg, he notes. With another treatment-related SAE, the analyst expects enrollment at this high dose may prove challenging, and notes that while improved efficacy at the higher dose could offset AE issues, promising initial data from Sarepta (SRPT) and positive commentary from Pfizer (PFE) on its Gene Tx program limit upside. Auster also lowered his price target on Solid's shares to $6 from $7.

SLDB

Solid Biosciences

$8.86

-0.3397 (-3.69%)

SRPT

Sarepta

$112.12

-9.97 (-8.17%)

PFE

Pfizer

$40.60

-0.12 (-0.29%)

  • 14

    May

  • 16

    May

  • 18

    May

  • 31

    May

  • 06

    Jun

  • 13

    Jun

  • 19

    Aug

SLDB Solid Biosciences
$8.86

-0.3397 (-3.69%)

05/14/19
FBCO
05/14/19
DOWNGRADE
FBCO
Underperform
Solid Biosciences downgraded to Underperform from Neutral at Credit Suisse
02/08/19
GSCO
02/08/19
NO CHANGE
Target $21
GSCO
Buy
Goldman says Orchard track record stands out amid disappointments in gene space
Goldman Sachs analyst Graig Suvannavejh noted that February 7 was "a day of disappointment" in the gene therapy and gene editing space, as Solid Biosciences (SLDB) and Sangamo (SGMO) both reported clinical efficacy data that missed investor expectations and "perhaps also raised concerns about the long-term promise of gene-based approaches." Within this context, he pointed out that he believes Orchard Therapeutics (ORTX) has "the most robust clinical experience in gene therapy, with over 150 patients treated across multiple product candidates and indications." The analyst, who expects new clinical data for Orchard candidates OTL-101 and OTL-102 to be presented later this month to re-affirm his confidence, reiterated his Buy rating and $21 price target on Orchard shares.
02/25/19
FBCO
02/25/19
NO CHANGE
Target $47
FBCO
Neutral
Roche may spark another bull run for gene therapy names, says Credit Suisse
Credit Suisse analyst Martin Auster notes that the Wall Street Journal recently reported that Roche (RHHBY) is nearing a deal with Spark Therapeutics (ONCE) for $5B. The analyst believes the transaction value implies the re-emergence of Spark's hemophilia A gene therapy program with a competitive profile and substantial value assigned to additional pipeline programs, such as SPK-3006 for Pompe, and the technology platform. Spark's acquisition would further strengthen the company's position in the hemophilia space, he contends. Further, Auster argues that the deal may increase M&A interest among other gene therapy names in his coverage universe, which include BioMarin (BMRN), Sarepta (SRPT), Ultragenyx (RARE), PTC (PTC) and Solid Biosciences (SLDB). He sees particularly strong read-through to Sarepta. The analyst reiterates a Neutral rating and a $47 price target on Spark's shares.
05/14/19
GSCO
05/14/19
DOWNGRADE
Target $4
GSCO
Sell
Solid Biosciences downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Solid Biosciences (SLDB) to Sell from Neutral after the company disclosed additional safety events with the first patient treated at the new high dose in the Phase 1/2 micro-dystrophin gene therapy study in Duchenne muscular dystrophy. Richter, who noted that he has previously expressed concern regarding a higher SGT-001 dose given safety events at the low dose, sees continued risk with the SGT-001 program as the trial continues to enroll, he tells investors. The analyst, who views SGT-001 as "suboptimal" versus competitor Sarepta's (SRPT) gene therapy, cut his price target on Solid shares to $4 from $5.
SRPT Sarepta
$112.12

-9.97 (-8.17%)

05/09/19
PIPR
05/09/19
NO CHANGE
Target $208
PIPR
Overweight
Sarepta continues to make progress in gene therapy, says Piper Jaffray
Sarepta Therapeutics continues to make progress on all fronts with their gene therapy platform, Piper Jaffray analyst Danielle Brill tells investors in a research note following the company's Q1 results. Sarepta has now dosed 18 patients in their ongoing microdystrophin gene therapy trial, and remain on track to complete dosing in Q2, says the analyst. She reiterates an Overweight rating on the shares with a $208 price target.
05/09/19
BARD
05/09/19
NO CHANGE
BARD
Outperform
Baird names Sarepta a 'Fresh Pick' ahead of Pfizer data
Baird analyst Brian Skorney named Sarepta as a "Fresh Pick" ahead of the report of competitive data due in late June from Pfizer's (PFE) Duchenne muscular dystrophy program that he predicts will "fall flat." If that turns out to be the case, it should remove the most significant overhang on Sarepta shares, contends Skorney, who keeps an Outperform rating on Sarepta.
04/17/19
BTIG
04/17/19
NO CHANGE
Target $190
BTIG
Buy
Sarepta remains in leading position on DMD and LGMD, says BTIG
BTIG analyst Timothy Chiang kept his Buy rating and $190 price target on Sarepta after attending the MDA Clinical & Scientific Conference this week, saying that its AAVrh74 gene therapies have received "a lot of attention" in the areas of Duchenne Muscular Dystrophy, or DMD, and Limb Girdle Muscular Dystrophy, or LGMD. The analyst also notes that many of the sessions discussing novel potential gene therapies for DMD/LGMD have been "packed with physicians / scientists / industry reps", adding that manufacturing scale up for gene therapies has also been widely discussed.
PFE Pfizer
$40.60

-0.12 (-0.29%)

05/07/19
ROTH
05/07/19
NO CHANGE
Target $51
ROTH
Buy
Eidos Therapeutics raised to $51 from $28 at Roth Capital
Roth Capital analyst Yasmeen Rahimi raised her price target for Eidos Therapeutics (EIDX) to $51 from $28 driven by an increase in AG10's annual price from $150,000 to $225,000 and Probability of Success adjustment from 70% to 80% after Pfizer's (PFE) tafamadis received U.S. approval with a high sticker price of $225,000, two months ahead of schedule. The analyst believes this makes life easier for Eidos Therapeutics to maintain and even expedite enrollment into its Phase 3 ATTRibute-CM trial. Rahimi reiterates a Buy rating on Eidos Therapeutics shares.
02/26/19
LEHM
02/26/19
NO CHANGE
LEHM
Galapagos weakness could be tied to Pfizer safety alert, says Barclays
Barclays believes the weakness today in Galapagos NV (GLPG) could be attributed to, at least in part, the FDA's safety communication on Pfizer's (PFE) post-marketing study of 10mg daily Xeljanz. Competitor safety issues with higher dose JAK inhibitors was a major focus of Galapagos' post-earnings conference call last week, Barclays tells investors in a research note. Galapagos management, while limited in what it can say pending the data, seems to believe they can get both doses approved, Barclays contends. Further, the firm points out that the company has received no communication and sees no reason to conclude that the FDA has determined that thromboembolic events are a class effect of the JAKs. Shares of Galapagos are down 1.5%, or $1.45, to $97.28 in late morning trading.
05/13/19
WELS
05/13/19
NO CHANGE
WELS
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."

TODAY'S FREE FLY STORIES

PINS

Pinterest

$26.69

0.68 (2.61%)

08:37
05/18/19
05/18
08:37
05/18/19
08:37
Periodicals
Pinterest committed 'cardinal sin' for newly public company, Barron's says »

Pinterest released its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSHB

KushCo Holdings

$0.00

(0.00%)

08:32
05/18/19
05/18
08:32
05/18/19
08:32
Periodicals
Pot paraphernalia companies taking hit from tariffs, Barron's says »

The U.S.-China trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

JWN

Nordstrom

$37.09

0.16 (0.43%)

08:24
05/18/19
05/18
08:24
05/18/19
08:24
Periodicals
Nordstrom stock a 'can't miss bargain.' Barron's says »

Nordstrom remains the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

NTDOY

Nintendo

$0.00

(0.00%)

, TTWO

Take-Two

$106.76

-0.81 (-0.75%)

08:10
05/18/19
05/18
08:10
05/18/19
08:10
Periodicals
Take-Two 'winning the game,' Barron's says »

Videogame stocks are down…

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$106.76

-0.81 (-0.75%)

DIS

Disney

$135.04

-0.46 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 24

    Jun

  • 13

    Nov

TPR

Tapestry

$30.78

-0.56 (-1.79%)

, REGN

Regeneron

$304.81

-4.69 (-1.52%)

08:01
05/18/19
05/18
08:01
05/18/19
08:01
Periodicals
Regeneron, Tapestry among cheap stocks to ride out trade war, Barron's says »

Applied Materials (AMAT),…

TPR

Tapestry

$30.78

-0.56 (-1.79%)

REGN

Regeneron

$304.81

-4.69 (-1.52%)

SCHW

Charles Schwab

$43.21

-0.94 (-2.13%)

BWA

BorgWarner

$36.27

-0.375 (-1.02%)

AMAT

Applied Materials

$42.72

-1.56 (-3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

  • 31

    May

  • 06

    Jun

  • 14

    Jun

  • 26

    Jun

  • 25

    Jul

MT

ArcelorMittal

$16.37

-0.485 (-2.88%)

, CLF

Cleveland-Cliffs

$10.02

-0.08 (-0.79%)

07:25
05/18/19
05/18
07:25
05/18/19
07:25
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

MT

ArcelorMittal

$16.37

-0.485 (-2.88%)

CLF

Cleveland-Cliffs

$10.02

-0.08 (-0.79%)

SCHN

Schnitzer Steel

$23.16

0.42 (1.85%)

BRSS

Global Brass and Copper

$43.09

-0.01 (-0.02%)

LXFR

Luxfer

$25.41

-0.44 (-1.70%)

MTRN

Materion

$66.36

0.155 (0.23%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$14.84

-0.01 (-0.07%)

F

Ford

$10.29

-0.1 (-0.96%)

GM

General Motors

$37.00

-0.36 (-0.96%)

HMC

Honda

$25.64

-0.135 (-0.52%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.40

-1.44 (-1.20%)

VWAGY

Volkswagen

$0.00

(0.00%)

SHOO

Steven Madden

$31.49

-0.37 (-1.16%)

GIII

G-III Apparel

$31.82

-0.35 (-1.09%)

IIVI

II-VI

$32.66

-1.64 (-4.78%)

LITE

Lumentum

$46.30

-4.15 (-8.23%)

MU

Micron

$36.06

-1.37 (-3.66%)

WDC

Western Digital

$44.62

-0.82 (-1.80%)

COHR

Coherent

$121.28

-5.22 (-4.13%)

LASR

nLight

$21.21

-1.27 (-5.65%)

VECO

Veeco

$12.50

-0.25 (-1.96%)

NPTN

NeoPhotonics

$3.83

-0.7 (-15.45%)

AAPL

Apple

$188.97

-0.93 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 28

    May

  • 29

    May

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 23

    Oct

WMT

Walmart

$100.88

-0.56 (-0.55%)

17:59
05/17/19
05/17
17:59
05/17/19
17:59
Hot Stocks
Walmart EVP Furner sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 15

    Aug

  • 13

    Nov

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

, REPYY

Repsol

$0.00

(0.00%)

17:56
05/17/19
05/17
17:56
05/17/19
17:56
Periodicals
Exxon Gulf of Mexico sale gets interest from Repsol, Ineos, Bloomberg says »

Exxon Mobil (XOM) has…

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

REPYY

Repsol

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

IEF

iShares 7-10 Year Treasury Bond ETF

$106.74

0.04 (0.04%)

, SHY

iShares 1-3 Year Treasury Bond

$84.15

0.02 (0.02%)

17:43
05/17/19
05/17
17:43
05/17/19
17:43
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$106.74

0.04 (0.04%)

SHY

iShares 1-3 Year Treasury Bond

$84.15

0.02 (0.02%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

SLV

iShares Silver Trust

$13.52

-0.14 (-1.02%)

GLD

SPDR Gold Shares

$120.64

-0.86 (-0.71%)

FXE

Euro Currency Trust

$106.35

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

17:39
05/17/19
05/17
17:39
05/17/19
17:39
Periodicals
IMF's Lagarde: U.S.-China trade spat may be risk to global economy, Reuters says »

IMF managing director…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIG

Hartford Financial

$53.58

-0.02 (-0.04%)

17:34
05/17/19
05/17
17:34
05/17/19
17:34
Syndicate
Breaking Syndicate news story on Hartford Financial »

Hartford Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

AFH

Atlas Financial

$0.91

0.0225 (2.53%)

17:33
05/17/19
05/17
17:33
05/17/19
17:33
Hot Stocks
Atlas Financial receives filing delinquency notice from Nasdaq »

Atlas Financial received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WES

Western Gas Partners

$30.60

-0.155 (-0.50%)

17:29
05/17/19
05/17
17:29
05/17/19
17:29
Syndicate
Breaking Syndicate news story on Western Gas Partners »

Western Gas Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$354.99

0.5 (0.14%)

17:24
05/17/19
05/17
17:24
05/17/19
17:24
Hot Stocks
Boeing awarded $163.91M Navy contract modification »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

LMT

Lockheed Martin

$338.10

-2.39 (-0.70%)

17:18
05/17/19
05/17
17:18
05/17/19
17:18
Hot Stocks
Lockheed Martin subsidiary awarded $1.13B Navy contract modification »

Sikorsky, a Lockheed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

COTY

Coty

$13.50

0.25 (1.89%)

17:14
05/17/19
05/17
17:14
05/17/19
17:14
Hot Stocks
Coty exec Pieraccioni acquires 93,100 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMR

Alta Mesa Resources

$0.18

-0.0027 (-1.50%)

17:14
05/17/19
05/17
17:14
05/17/19
17:14
Hot Stocks
Alta Mesa Resources receives noncompliance notification from Nasdaq »

Nasdaq notified Alta Mesa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NJR

New Jersey Resources

$49.82

-0.03 (-0.06%)

17:06
05/17/19
05/17
17:06
05/17/19
17:06
Hot Stocks
New Jersey Resources' Trice sells 12,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

AHC

A.H. Belo

$3.82

-0.075 (-1.93%)

17:03
05/17/19
05/17
17:03
05/17/19
17:03
Hot Stocks
A.H. Belo sells former Dallas Morning News campus for $31.6M »

A. H. Belo announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRA

Telaria

$8.56

0.2 (2.39%)

17:01
05/17/19
05/17
17:01
05/17/19
17:01
Hot Stocks
Telaria director Rossman sells 173K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 10

    Jun

HL

Hecla Mining

$1.53

0.015 (0.99%)

16:58
05/17/19
05/17
16:58
05/17/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INNT

Innovate Biopharmaceuticals

$1.59

-0.095 (-5.65%)

16:57
05/17/19
05/17
16:57
05/17/19
16:57
Syndicate
Breaking Syndicate news story on Innovate Biopharmaceuticals »

Innovate files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 31

    May

JONE

Jones Energy

$0.00

(0.00%)

16:56
05/17/19
05/17
16:56
05/17/19
16:56
Hot Stocks
Jones Energy emerges from bankruptcy »

Jones Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPP

Hudson Pacific

$34.33

-0.15 (-0.44%)

16:44
05/17/19
05/17
16:44
05/17/19
16:44
Hot Stocks
Hudson Pacific CFO sells ~57K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

GLYC

GlycoMimetics

$12.42

-0.43 (-3.35%)

16:36
05/17/19
05/17
16:36
05/17/19
16:36
Syndicate
Breaking Syndicate news story on GlycoMimetics »

GlycoMimetics files $250M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.